Pill Reduce Relapses in MS Patients
According to the report, the study of which was led by researcher Dr. Giancarlo Comi of Vita-Salute San Raffaele University in
Three years on the said clinical trials, 67 percent of the 173 patients who took FTY720 orally were free of relapses. 89 percent of the patients were free of any disease activity while 75 percent of the patients were found not to have developed new lesions or see their previous lesions getting any larger, as confirmed from their MRI scans. Dr. Comi further added, “The first-line treatments for MS, beta interferon and glatiramer acetate, reduce the relapse rate by only about 30 percent, so this is a significant development for people with MS.”
FTY720 works by binding itself into the receptors on immune cells and isolating them in the lymph nodes. This reduces the ability of the immune cells to cause damage to the nerve cells that is associated with symptoms of multiple sclerosis. Side effects reported by patients included headache, cold and flu symptoms.
Source: healthday.com
Posted inMSNews | | You can leave a response, or trackback from your own site.


I have been watching the outcome of this small study. If this can be reproduced in a larger study, this will be a HUGE Break through for MS pt’s and their families.
Bring it on and quickly. If it works lets get it it approved by regulatory agencys fast